69.00
-0.50
(-0.72%)
Real-time:
3:01pm BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 67.00 - 70.00 |
| 52 week | 24.00 - 74.00 |
| Open | 70.00 |
| Vol / Avg. | 365,003.00/261.00 |
| Mkt cap | 132.82M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.02* |
| Shares | 192.50M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jun 21, 2013
Proteome Sciences PLC Annual General Meeting
|
|
Key stats and ratios
| Q2 (Jun '12) | 2011 | |
| Net profit margin | -133.58% | -387.53% |
| Operating margin | -175.94% | -425.13% |
| EBITD margin | - | -405.01% |
| Return on average assets | -22.94% | -29.86% |
| Return on average equity | -86.86% | -75.25% |
| Employees | 38 | - |
| Carbon Disclosure Rating | - | - |
Address
Coveham House, Downside Bridge Road
COBHAM, ENG KT11 3EP
United Kingdom - Map
+44-1932-865065 (Phone)
+44-1932-868696 (Fax)
COBHAM, ENG KT11 3EP
United Kingdom - Map
+44-1932-865065 (Phone)
+44-1932-868696 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Proteome Sciences plc is engaged in biomarker research and development in applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. It is a Protein Biomarker Discovery Service company specializing in Proteomics and Peptidomics applications and a mass spectrometry protein company. The Company�s three geographic segments include: United Kingdom, Germany and the United States. The main focus of research is to address neurological, neurodegenerative, cardiovascular and cancer conditions and blood biomarkers in stroke, brain damage, solid organ transplant rejection and Alzheimer�s disease. The company�s subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc. and Phenomics Limited.
Officers and directors
| Christopher D.J. Pearce | Chief Executive, Executive Director | |
| James L. Malthouse | Finance Director, Company Secretary, Executive Director | |
| Ian H. Pike | Chief Operating Officer, Executive Director | |
| Malcolm Ward | Chief Technical Officer - London Research Facility | |
| Hans-Dieter Zucht | Chief Technical Officer - Proteome Sciences R&D, Frankfurt | |
| Glenn Barney | Vice President - Business Development, USA | |
| Josef Schwarz | Head - Projects & Production, Proteome Sciences R&D | |
| Rainer Voegeli | Commercial Director, Europe | |
| R. S. Harris | Non-Executive Chairman of the Board | |
| William Dawson | Non-Executive Director |